Riskpilot← Back to searchSign inGet full accessTLA Targeted Immunotherapies AB
ABBankruptOrg 5567040042SollentunaResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20060 employees
Revenue 2023
SEK 446K
-78% vs 2022
EBITDA margin
-1412.6%
-9% vs 2022
Equity ratio
-74.7%
Financial strength
Net profit 2023
SEK -10,8M
-17% vs 2022
| Revenue | SEK 446K | -78% |
| EBITDA | SEK -6,3M | -9% |
| Net profit | SEK -10,8M | -17% |
| Total assets | SEK 29,7M | -1% |
| Equity | SEK -22,2M | -95% |
| Employees | 0 | — |
Legal name
TLA Targeted Immunotherapies AB
Org number
5567040042
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
12 maj 2006
Share capital
SEK 262 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2023-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Föremålet för bolagets verksamhet är att inom cellterapi bedriva forskning och idéutveckling, klinisk prövning av forskning samt kommersialisering av forskning. Vidare ska bolaget även starta och förvalta nya bolag inom cellterapi området samt idka därmed förenlig verksamhet.
Address
Sollentuna
Phone
+46705772412
Email
tarek@ekonomilanken.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Revenue | 19 204 | 15 968 | 1 817 | 1 993 | 446 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −370 | 16 | −4 902 | −5 761 | −6 300 |
| Depreciation & amort. | −281 | −257 | −784 | −2 622 | −3 269 |
| EBIT | −651 | −241 | −5 686 | −8 383 | −9 569 |
| Net financials | 657 | −345 | −656 | −816 | −1 203 |
| Profit before tax | 5 | −586 | −6 342 | −9 198 | −10 773 |
| Tax | −11 | −0 | −0 | −0 | −0 |
| Net profit | −6 | −586 | −6 342 | −9 198 | −10 773 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| Total assets | 16 580 | 25 002 | 29 668 | 29 848 | 29 681 |
| Equity | 237 | 4 151 | −2 191 | −11 389 | −22 162 |
| Long-term debt | 0 | 14 925 | 15 474 | 16 248 | 12 255 |
| Short-term debt | 16 343 | 5 926 | 16 385 | 24 990 | 39 588 |
| Total debt | 16 343 | 20 851 | 31 859 | 41 238 | 51 843 |
EBITDA margin
-1412.6%
This company
15.8%
Market median
-9041% vs market
20192023
Equity ratio
-74.7%
This company
38.2%
Market median
-296% vs market
20192023
Return on equity
-1077300000.0%
This company
18.4%
Market median
-5854891404% vs market
20192023
Net profit margin
-2415.5%
This company
8.1%
Market median
-29921% vs market
20192023
Asset turnover
0.02×
This company
1.12×
Market median
-98% vs market
20192023
Debt / equity
2.34×
This company
0.62×
Market median
-277% vs market
20192023
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
SJ Chief Executive Officer | Chief Executive Officer | 2021 |
JH Chief Auditor | Chief Auditor | 2020 |
| Former (1) | ||
AA Chief Executive Officer | Chief Executive Officer | 2020 – 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2020 | |
| Chairman | 2021 | |
| Former (1) | ||
| Chairman | 2020 – 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of TLA Targeted Immunotherapies AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ahsan Amjad | Chief Executive Officer | 0 companies |
| Stig Jonas Winqvist | Chief Executive Officer | 0 companies |
| Johan Henrik Magnusson Luther | Chief Auditor | 0 companies |
| Hans Olof Glise | Chairman | 0 companies |
| Åke Stefan Warin | Board of Directors | 0 companies |
| Stig Ola Winqvist | Chairman | 0 companies |